Joseph Daval

Postdoc fellow @PORTAL_Research.
@YaleLawSch '21; @ASU '18.

[Joseph Daval @DavalJoseph]

When @US_FDA goes to court, @TheJusticeDept is its lawyer. But how does DOJ control of litigation shape FDA policy? I interviewed 20 former FDA and DOJ attorneys for my Article "Litigating Authority for the FDA" https://t.co/HFlAAePUdl

[Joseph Daval @DavalJoseph]

FDA uses advisory committees for recs on new drug approvals, but how does EMA use its scientific advisory groups?

New piece in @JournalGIM from @PORTAL_Research with @AmeetSarpatwari, @LeighSharpless, and @akesselheim

https://t.co/1IxhXuqz2V

[Rep. Frank Pallone @FrankPallone]

Big Pharma's legal arguments against price negotiation are absurd. Pharmaceutical manufacturers are not entitled to limitless profits at the expense of the American taxpayer. They should not abuse the legal system to stop the IRA's drug price provisions from going into effect.

[Joseph Daval @DavalJoseph]

My op-ed today in @washingtonpost with @akesselheim on the Medicare drug lawsuits: https://t.co/axwCsDHEtu

Their arguments rely on the untenable premise that for-profit companies have a constitutionally protected right to receive taxpayer dollars.

[Joseph Ross @jsross119]

Nice piece @DavalJoseph on protecting @CMSGov's coverage discretion: "A system in which taxpayers are required to pay for inferior treatments is not a competitive marketplace—it is an entitlement program for for-profit companies subsidized by the public" https://t.co/GZohBWTtFa

[Ben Rome @bnrome]

🔥 🔥 🔥 @JAMA_current viewpoint by @DavalJoseph @LiamBendicksen @akesselheim.

Protecting Medicare’s Discretion to Say No to Unproven Therapies

https://t.co/nHU6B1L2eY

[Joseph Daval @DavalJoseph]

"A system in which taxpayers are required to pay for inferior treatments is not a competitive marketplace—it is an entitlement program for for-profit companies subsidized by the public."

[Joseph Daval @DavalJoseph]

My latest in JAMA with @LiamBendicksen and @akesselheim from @PORTAL_Research:

Protecting Medicare’s Discretion to Say No to Unproven Therapies

https://t.co/rJbFLMHUuV

[William Feldman @wbfeldman]

We had our annual @PORTAL_Research retreat yesterday! Always inspired by this group.

Looking forward to the year ahead in pharmaceutical policy!

[Joseph Daval @DavalJoseph]

@pash22 @jsross119 @DanClintonRN @gregggonsalves @shakespeare34 @ProfRobHoward @PhilAlz @nvillain_alz @matthewherper @DrTFromKC @seb_walsh @smead2 @LonSchneiderMD @AlbertoEspay @Kariem_Ezzat @JosephTherr @dmrind @MadhavThambiset @Scott_M_Reid @EWidera @RenegadeSynapse @LogarithmicDis @KasperKepp @Jennife10651535 @pxrobbo @MemoryDoc @metapredict @CorriveauNick @DavidJonesBrain @eturnermd1 @kateeeemily @StefanoSensi14 @VincentPlanche @ayton_scott @reshmagar @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @schrag_matthew @kathy_y_liu @naomikresge @MedicareGov No worries—one of the benefits of getting confused with the inimitable @jsross119 is that Twitter always lets him know when I publish a new paper!

[Joseph Daval @DavalJoseph]

With a great commentary by @ProfGenKanter:

https://t.co/WNh8s7cTWT

[Joseph Daval @DavalJoseph]

New papers!

Today in @JAMAInternalMed with @akesselheim @PORTAL_Research:

Can Medicare limit coverage of FDA-approved products? Yes, and it does.

https://t.co/y8nYy1rIZi

[Joseph Daval @DavalJoseph]

And (a few weeks ago) in @JAMAHealthForum with @akesselheim @argMaxRusso & Theodore Teng @PORTAL:

Dramatic decrease in FDA use of drug advisory committees, but FDA continues to follow their recommendations in most cases.

https://t.co/q5fyjwwlZo

[JAMA Health Forum @JAMAHealthForum]

Consistent alignment with advisory recommendations, along with an overall decrease in meetings, suggests that FDA is leaning away from independent expert advice even as it continues to follow it, according to this quality improvement study. https://t.co/meelHTpXdz @akesselheim

[NEJM @NEJM]

The FDA has long conducted its oversight of prescription drugs and other products with deference from courts. But mounting judicial skepticism of agency authority threatens to upend this norm. https://t.co/hhYGve4CTz

[Program On Regulation, Therapeutics, And Law @PORTAL_Research]

New @PORTAL_Research perspective out @NEJM this week from @DavalJoseph @LiamBendicksen @akesselheim

[Joseph Daval @DavalJoseph]

With amazing co-authors @LiamBendicksen and @akesselheim

https://t.co/8CkFCVMUky

[Joseph Daval @DavalJoseph]

How will the major questions doctrine affect FDA's authority to protect public health?

Excited to share a new @NEJM Perspective from @PORTAL_Research: "Eroding Judicial Deference to the FDA—Consequences for Public Health"

[Joseph Daval @DavalJoseph]

@amarimow @washingtonpost Ah I see, that does help, thank you!

[Aaron Kesselheim @akesselheim]

Pleased to announce a recent small grant from the IBM Center for The Business of Government to support a comprehensive report on FDA Advisory Committee performance and reform led by @PORTAL_Research fellow @DavalJoseph coming in 2023: https://t.co/CJ960yt3jI